Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Journal of Molecular Biology|November 20, 1987
Mechanisms of ultraviolet-induced mutation. Mutational spectra in the Escherichia coli lacI gene for a wild-type and an excision-repair-deficient strainR M Schaaper, R L Dunn, B W Glickman
AAPS Pharmscitech|January 20, 2004
Sustained activity and release of leuprolide acetate from an in situ forming polymeric implantH B Ravivarapu, K L Moyer, R L Dunn
Journal of Pharmaceutical Sciences|May 29, 2000
Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetateH B Ravivarapu, K L Moyer, R L Dunn
International Journal of Pharmaceutics|February 29, 2000
Parameters affecting the efficacy of a sustained release polymeric implant of leuprolideH B Ravivarapu, K L Moyer, R L Dunn
Journal of Bacteriology|December 11, 1997
Genetic requirements and mutational specificity of the Escherichia coli SOS mutator activityI J Fijalkowska, R L Dunn, R M Schaaper
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 6, 2006
Controlling for systematic selection in retrospective analyses: an application to fluoxetine and sertraline prescribing in the United KingdomC A Neslusan, T R Hylan, R L Dunn, et al.
Journal of the National Cancer Institute|February 17, 2000
Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cellsR Wu, D C Connolly, R L Dunn, et al.
International Clinical Psychopharmacology|December 23, 1998
Gaps in antidepressant prescribing in primary care in the United KingdomT R Hylan, R L Dunn, R G Tepner, et al.
Journal of Bacteriology|June 15, 2000
Hypersensitivity of Escherichia coli Delta(uvrB-bio) mutants to 6-hydroxylaminopurine and other base analogs is due to a defect in molybdenum cofactor biosynthesisS G Kozmin, Y I Pavlov, R L Dunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancerD C Smith, R L Dunn, M S Strawderman, et al.
Pageof 7